ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol - A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness
ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol - A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness
复制标题
DOI：
10.1161/01.cir.0000034508.55617.65
复制
发表时间：
2002-10-15
期刊：
影响因子：
37.8
通讯作者：
Vernalis, MN
中科院分区：
文献类型：
--
作者：
Taylor, AJ;Kent, SM;Vernalis, MN
背景-LDL显著降低至远低于100 mg/dL的水平是否会进一步降低心血管疾病的负担仍有争议。我们比较了两种他汀类药物降低LDL的作用，方法和结果：这是一项纳入161例患者的单中心、随机、临床试验（平均年龄60岁; 71.4%为男性; 46%患有已知的心血管疾病），符合国家胆固醇教育计划（NCEP）II降脂治疗标准。采用盲法对颈总动脉远端壁进行系列评估，比较阿托伐他汀（80 mg/d; n=79）和普伐他汀（40 mg/d; n=82）对CIMT的影响。研究组之间的基线CIMT和其他特征相似。正如预期的那样，阿托伐他汀在12个月后降低LDL的作用明显更强：在阿托伐他汀组中，12个月后LDL胆固醇为76 23 mg/dL（-48.5%）;普伐他汀组的LDL胆固醇为110 30 mg/dL（-27.2%; P
Background-Whether marked LDL reduction to levels well below 100 mg/dL would further reduce the burden of cardiovascular disease is controversial. We compared the effects of 2 statins with widely differing potencies for LDL reduction (pravastatin 40 mg/d and atorvastatin 80 mg/d) on carotid intima-media thickness (CIMT).Methods and Results-This was a single-center, randomized, clinical trial of 161 patients (mean age, 60 years; 71.4% male; 46% with known cardiovascular disease) that met National Cholesterol Education Program (NCEP) II criteria for lipid-lowering therapy. The effects of atorvastatin (80 mg/d; n=79) and pravastatin (40 mg/d; n=82) on CIMT were compared using blinded, serial assessments of the far wall of the distal common carotid artery. Baseline CIMT and other characteristics were similar between study groups. As anticipated, atorvastatin was substantially more potent for LDL reduction after 12 months: in the atorvastatin group, LDL cholesterol was 76 23 mg/dL after 12 months (-48.5%); LDL cholesterol was 110 30 mg/dL in the pravastatin group (-27.2%; P